VA
TCRX icon

Verdad Advisers’s TScan Therapeutics TCRX Stock Holding History

Verdad Advisers’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$228K Buy
232,759
+98,758
+74% +$105K 0.22% 137
2026
Q1 		$135K Buy
+134,001
New +$143K 0.15% 144

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Verdad Advisers's TCRX Position: Q2 2026 in Review

Verdad Advisers increased its TScan Therapeutics (TCRX) stake by 74% in Q2 2026, buying an estimated $105K and bringing the position to 232,759 shares worth $228K. The position accounts for 0.22% of the portfolio, ranked #137.

Verdad Advisers first reported a position in TCRX in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • Verdad Advisers held 232,759 shares of TScan Therapeutics worth $228K as of Q2 2026.
  • Verdad Advisers bought 98,758 TScan Therapeutics shares in Q2 2026, an estimated $105K.
  • TScan Therapeutics made up 0.22% of Verdad Advisers's portfolio in Q2 2026, its #137 holding.
  • Verdad Advisers first reported a position in TScan Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.